Summary
Neuropeptide Y (NPY) is one of the most abundant peptide in the brain and has been implicated in various biological functions. Pre-clinical and clinical investigations have suggested that NPY, acting on specific receptors, has direct role in several psychiatric disorders, including depression and anxiety-related illnesses, which will be reviewed in this chapter. Increasing support for a role for NPY in mood disorders has been obtained over the past few years. The Y1, Y2 and Y4 receptor subtypes have been particularly involved in these behaviours. For example, we reported that NPY Y2 knockout mice display anxiolytic-like phenotype as assessed in the elevated plus maze and open field tests, suggesting a role of this receptor subtype in anxiety-related behaviours. Moreover, NPY Y2 knockout mice display memory retention deficits as evaluated in the Morris water maze and object recognition tests, while acquisition performance, swim speed and visible platform performance were not significantly different between knockout and wild-type mice. Additionally, young and old rats overexpressing NPY were found to be resistant to acute physical restrain stress, but rather surprisingly, no memory deficit was observed in old transgenic rats, contrasting with data obtained in young transgenic animals. Aged NPY transgenic rats and NPY Y2 knockout mice exhibit anxiolytic-like phenotypes, in accordance with results observed in younger animals. Interestingly, the ontogeny of various NPY receptor subtypes suggest further that they may be implicated in the etiology of anxiety-like phenotype observed in maternally deprived animals as important changes in NPY receptor distribution and levels occur during this critical period, especially for the Y2 receptor subtype. Taken together, these results support the hypothesis that NPY and its receptors may be involved in the regulation of anxiety-related behaviours and provide evidence that this neuropeptide family is an attractive drug development target for these disorders.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Acuna-Goycolea C, Tamamaki N, Yanagawa Y, Obata K, van den Pol AN (2005) Mechanisms of neuropeptide Y, peptide YY, and pancreatic polypeptide inhibition of identified green fluorescent protein-expressing GABA neurons in the hypothalamic neuroendocrine arcuate nucleus. J.Neurosci 25:7406–7419
Albers HE, Ferris CF (1984) Neuropeptide Y: role in light-dark cycle entrainment of hamster circadian rhythms. Neurosci.Lett. 50:163–168
Aoki C, Pickel VM (1989) Neuropeptide Y in the cerebral cortex and the caudate-putamen nuclei: ultrastructural basis for interactions with GABAergic and non-GABAergic neurons. J.Neurosci. 9:4333–4354
Asakawa A, Inui A, Ueno N, Fujimiya M, Fujino MA, Kasuga M (1999) Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides 20:1445–1448
Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M, Fujino MA, Niijima A, Meguid MM, Kasuga M (2003) Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124:1325–1336
Bannon AW, Seda J, Carmouche M, Francis JM, Norman MH, Karbon B, McCaleb ML (2000) Behavioral characterization of neuropeptide Y knockout mice. Brain Res. 868:79–87
Belzung C, Griebel G (2001) Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav.Brain Res. 125:141–149
Blomqvist AG, Herzog H (1997) Y-receptor subtypes—how many more? Trends Neurosci. 20:294–298
Boulenger JP, Jerabek I, Jolicoeur FB, Lavallee YJ, Leduc R, Cadieux A (1996) Elevated plasma levels of neuropeptide Y in patients with panic disorder. Am.J.Psychiatry 153:114–116
Breslau N, Schultz L, Peterson E (1995) Sex differences in depression: a role for preexisting anxiety. Psychiatry Res. 58:1–12
Britton KT, Southerland S, Van Uden E, Kirby D, Rivier J, Koob G (1997) Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology(Berl) 132:6–13
Britton KT, Akwa Y, Spina MG, Koob GF (2000) Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze. Peptides 21:37–44
Broqua PP, Wettstein JJ, Rocher MM, Gauthier-Martin BB, Junien JJ (1995) Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav.Pharmacol. 6:215–222
Caldji C, Tannenbaum B, Sharma S, Francis D, Plotsky PM, Meaney MJ (1998) Maternal care during infancy regulates the development of neural systems mediating the expression of fearfulness in the rat. Proc.Natl.Acad.Sci.U.S A 95:5335–5340
Caldji C, Francis D, Sharma S, Plotsky PM, Meaney MJ (2000) The effects of early rearing environment on the development of GABAA and central benzodiazepine receptor levels and novelty-induced fearfulness in the rat. Neuropsychopharmacology 22:219–229
Carvajal CC, Vercauteren F, Dumont Y, Michalkiewicz M, Quirion R (2004) Aged neuropeptide Y transgenic rats are resistant to acute stress but maintain spatial and non-spatial learning. Behav.Brain Res. 153:471–480
Carvajal C, Dumont Y, Herzog H, Quirion R (2006a) Emotional behavior in aged neuropeptide Y (NPY) Y2 knockout mice. J.Mol.Neurosci 28:239–245
Carvajal C, Dumont Y, Quirion R (2006b) Neuropeptide Y: role in emotion and alcohol dependence. CNS Neurol.Disord.Drug Targets 5:181–195
Carvajal C, Dumont Y, Quirion R (2007) Neuropeptide Y. In: Fink G (ed) Encyclopedia of Stress, Second Edition, Volume 2. Academic Press, Oxford, UK, pp 895–903
Clark JT, Kalra PS, Kalra SP (1985) Neuropeptide Y stimulates feeding but inhibits sexual behavior in rats. Endocrinology 117:2435–2442
Colmers WF, Lukowiak K, Pittman QJ (1987) Presynaptic action of neuropeptide Y in area CA1 of the rat hippocampal slice. J.Physiol (Lond) 383:285–299
Dumont Y, Quirion R (2000) [125I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y1 and Y4 receptors. Br.J.Pharmacol. 129:37–46
Dumont Y, Quirion R (2006) An overview of neuropeptide Y: pharmacology to molecular biology and receptor localization. In: Zukowska Z, Feuerstein GZ (eds) NPY Family of Peptides in Neurobiology, Cardiovascular and Metabolism Disorders: from Genes to Therapeutics. Birkhauser Verlag, Berlin, Germany, pp 7–33
Dumont Y, Fournier A, St Pierre S, Quirion R (1996) Autoradiographic distribution of[125I][Leu31,Pro34]PYY and [125I]PYY3-36 binding sites in the rat brain evaluated with two newly developed Y1 and Y2 receptor radioligands. Synapse 22:139–158
Dumont Y, Fournier A, Quirion R (1998a) Expression and characterization of the neuropeptide Y Y5 receptor subtype in the rat brain. J.Neurosci. 18:5565–5574
Dumont Y, Jacques D, Bouchard P, Quirion R (1998b) Species differences in the expression and distribution of the neuropeptide Y Yl, Y2, Y4 and Y5 receptors in rodents, guinea pig and primates brains. J.Comp Neurol. 402:372–384
Dumont Y, Cadieux A, Doods H, Fournier A, Quirion R (2000a) Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Yl) and CGP71683A (Y5). Can.J.Physiol Pharmacol. 78:116–125
Dumont Y, Cadieux A, Doods H, Pheng LH, Abounader R, Hamel E, Jacques D, Regoli D, Quirion R (2000b) BIIE0246, a potent and highly selective nonpeptide neuropeptide Y Y2 receptor antagonist. Br.J.Pharmacol. 129:1075–1088
Dumont Y, Jacques D, St Pierre JA, Tong Y, Parker R, Herzog H, Quirion R (2000c) Neuropeptide Y, peptide YY and pancreatic polypeptide receptor proteins and rnRNAs in mammalian brains. In: Quirion R, Bjorklund A, Hokfelt T (eds) Handbook of Chemical Neuroanatomy, Vol 16 Peptide Receptors, Part 1. Elsevier, London, UK, pp 375–475
Dumont Y, Chabot JG, Quirion R (2004) Receptor autoradiography as mean to explore the possible functional relevance of neuropeptides: Focus on new agonists and antagonists to study natriuretic peptides, neuropeptide Y and calcitonin gene-related peptides. Peptides 25:365–391
Dumont Y, Moyse E, Fournier A, Quirion R (2005) Evidence for the existence of an additional class of neuropeptide Y receptor sites in the rat brain. J.Pharmacol.Exp.Ther. 315:99–108
Edvinsson L, Ekblad E, Hakanson R, Wahlestedt C (1984) Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br.J.Pharmacol. 83:519–525
Ekman R, Wahlestedt C, Bottcher G, Sundler F, Hakanson R, Panula P (1986) Peptide YY-like immunoreactivity in the central nervous system of the rat. Regul.Pept. 16:157–168
Esteban J, Chover AJ, Sanchez PA, Mico JA, Gibert-Rahola J (1989) Central administration of neuropeptide Y induces hypothermia in mice. Possible interaction with central noradrenergic systems. Life Sci. 45:2395–2400
Ferrara G, Serra M, Zammaretti F, Pisu MG, Panzica GC, Biggio G, Eva C (2001) Increased expression of the neuropeptide Y receptor Y(l) gene in the medial amygdala of transgenic mice induced by long-term treatment with progesterone or allopregnanolone. J.Neurochem. 79:417–425
File SE, Lippa AS, Beer B, Lippa MT (2004) Animal tests of anxiety. Curr.Protoc.Neurosci Chapter 8:Unit
Flood JF, Hernandez EN, Morley JE (1987) Modulation of memory processing by neuropeptide Y. Brain Res. 421:280–290
Griebel G (1999) Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol.Ther. 82:1–61
Harfstrand A (1986) Intraventricular administration of neuropeptide Y (NPY) induces hypotension, bradycardia and bradypnoea in the awake unrestrained male rat. Counteraction by NPY-induced feeding behaviour. Acta Physiol Scand. 128:121–123
Heilig M (1995) Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regul.Pept. 59:201–205
Heilig M (2004) The NPY system in stress, anxiety and depression. Neuropeptides 38:213–224
Heilig M, Murison R (1987) Intracerebroventricular neuropeptide Y suppresses open field and home cage activity in the rat. Regul.Pept. 19:221–231
Heilig M, Soderpalm B, Engel JA, Widerlov E (1989a) Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl) 98:524–529
Heilig M, Vecsei L, Widerlov E (1989b) Opposite effects of centrally administered neuropeptide Y (NPY) on locomotor activity of spontaneously hypertensive (SH) and normal rats. Acta Physiol Scand. 137:243–248
Heilig M, McLeod S, Koob GK, Britton KT (1992) Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an opérant conflict test. Regul.Pept. 41:61–69
Heilig M, McLeod S, Brot M, Heinrichs SC, Menzaghi F, Koob GF, Britton KT (1993) Anxiolytic-like action of neuropeptide Y: mediation by Yl receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 8:357–363
Heilig M, Koob GF, Ekman R, Britton KT (1994) Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci. 17:80–85
Horvath TL, Bechmann I, Naftolin F, Kalra SP, Leranth C (1997) Heterogeneity in the neuropeptide Y-containing neurons of the rat arcuate nucleus: GABAergic and non-GABAergic subpopulations. Brain Res. 756:283–286
Huot RL, Thrivikraman KV, Meaney MJ, Plotsky PM (2001) Development of adult ethanol preference and anxiety as a consequence of neonatal maternal separation in Long Evans rats and reversal with antidepressant treatment. Psychopharmacology (Berl) 158:366–373
Husum H, Mathe AA (2002) Early life stress changes concentrations of neuropeptide Y and corticotropin-releasing hormone in adult rat brain. Lithium treatment modifies these changes. Neuropsychopharmacology 27:756–764
Husum H, Termeer E, Mathe AA, Bolwig TG, Ellenbroek BA (2002) Early maternal deprivation alters hippocampal levels of neuropeptide Y and calcitoningene related peptide in adult rats. Neuropharmacology 42:798–806
Inui A (2000) Transgenic approach to the study of body weight regulation. Pharmacol.Rev. 52:35–61
Inui A, Okita M, Nakajima M, Momose K, Ueno N, Teranishi A, Miura M, Hirosue Y, Sano K, Sato M, Watanabe M, Sakai T, Watanabe T, Ishida K, Silver J, Baba S, Kasuga M (1998) Anxiety-like behavior in transgenic mice with brain expression of neuropeptide Y. Proc.Assoc.Am.Physicians 110:171–182
Jimenez-Vasquez PA, Mathe AA, Thomas JD, Riley EP, Ehlers CL (2001) Early maternal separation alters neuropeptide Y concentrations in selected brain regions in adult rats. Brain Res.Dev.Brain Res. 131:149–152
Kalra SP, Crowley WR (1984) Differential effects of pancreatic polypeptide on luteinizing hormone release in female rats. Neuroendocrinology 38:511–513
Kalra SP, Kalra PS (2006) Neuropeptide Y: A conductor of the appetite-regulating orchestra in the hypothalamus. In: Kastin AJ (ed) Handbook of Biologically Active Peptides. Acadenic Press, San Diego, USA, pp 889–894
Karl T, Herzog H (2007) Behavioral profiling of NPY in aggression and neuropsychiatrie diseases. Peptides 28:326–333
Karl T, Lin S, Schwarzer C, Sainsbury A, Couzens M, Wittmann W, Boey D, von Horsten S, Herzog H (2004) Y1 receptors regulate aggressive behavior by modulating serotonin pathways. Proc.Natl.Acad.Sci.U.S.A 101:12742–12747
Karl T, Burne TH, Herzog H (2006) Effect of Yl receptor deficiency on motor activity, exploration, and anxiety. Behav.Brain Res. 167:87–93
Karl T, Duffy L, Herzog H (2008) Behavioural profile of a new mouse model for NPY deficiency. Eur.J.Neurosci 28:173–180
Karlsson RM, Holmes A, Heilig M, Crawley JN (2005) Anxiolytic-like actions of centrally-administered neuropeptide Y, but not galanin, in C57BL/6J mice. Pharmacol.Biochem.Behav. 80:427–436
Karlsson RM, Choe JS, Cameron HA, Thorsell A, Crawley JN, Holmes A, Heilig M (2008) The neuropeptide Y Yl receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice. Psychopharmacology (Berl) 195:547–557
Kash TL, Winder DG (2006) Neuropeptide Y and corticotropin-releasing factor bi-directionally modulate inhibitory synaptic transmission in the bed nucleus of the stria terminalis. Neuropharmacology 51:1013–1022
Kask A, Rago L, Harro J (1996) Anxiogenic-like effect of the neuropeptide Y Yl receptor antagonist BIBP3226: antagonism with diazepam. Eur.J.Pharmacol. 317:R3–R4
Kask A, Nguyen HP, Pabst R, von Horsten S (2001) Neuropeptide Y Yl receptormediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced anxiety. Neuroscience 104:799–806
Kask A, Harro J, von Horsten S, Redrobe JP, Dumont Y, Quirion R (2002) The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci.Biobehav.Rev. 26:259–283
Kessler RC, Berglund P, Demier O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch.Gen.Psychiatry 62:593–602
Klapstein GJ, Colmers WF (1997) Neuropeptide Y suppresses epileptiform activity in rat hippocampus in vitro. J.Neurophysiol. 78:1651–1661
Koob GF, Heinrichs SC (1999) A role for corticotropin releasing factor and urocortin in behavioral responses to Stressors. Brain Res. 848:141–152
Krysiak R, Obuchowicz E, Herman ZS (1999) Diazepam and buspirone alter neuropeptide Y-like immunoreactivity in rat brain. Neuropeptides 33:542–549
Krysiak R, Obuchowicz E, Herman ZS (2000) Conditioned fear-induced changes in neuropeptide Y-like immunoreactivity in rats: the effect of diazepam and buspirone. Neuropeptides 34:148–157
Ladd CO, Huot RL, Thrivikraman KV, Nemeroff CB, Meaney MJ, Plotsky PM (2000) Long-term behavioral and neuroendocrine adaptations to adverse early experience. Prog.Brain Res. 122:81–103
Larhammar D (1996) Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Regul.Pept. 62:1–11
Leonardo ED, Hen R (2008) Anxiety as a developmental disorder. Neuropsychopharmacology 33:134–140
Lim S, Ryu YH, Kim ST, Hong MS, Park HJ (2003) Acupuncture increases neuropeptide Y expression in hippocampus of maternally-separated rats. Neurosci.Lett. 343:49–52
Lin S, Boey D, Herzog H (2004) NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides 38:189–200
Massari VJ, Chan J, Chronwall BM, O‘Donohue TL, Oertel WH, Pickel VM (1988) Neuropeptide Y in the rat nucleus accumbens: ultrastructural localization in aspiny neurons receiving synaptic input from GABAergic terminals. J.Neurosci.Res. 19:171–186
Mathew SJ, Price RB, Charney DS (2008) Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am.J.Med.Genet.C.Semin.Med.Genet. 148:89–98
McDonald AJ, Pearson JC (1989) Coexistence of GAB A and peptide immunoreactivity in non-pyramidal neurons of the basolateral amygdala. Neurosci.Lett. 100:53–58
McEwen BS (2000) The neurobiology of stress: from serendipity to clinical relevance. Brain Res. 886:172–189
McIntosh J, Anisman H, Merali Z (1999) Short-and long-periods of neonatal maternal separation differentially affect anxiety and feeding in adult rats: genderdependent effects. Brain Res.Dev.Brain Res. 113:97–106
Michalkiewicz M, Michalkiewicz T (2000) Developing transgenic neuropeptide Y rats. Methods Mol.Biol. 153:73–89:73–89
Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol.Rev. 50:143–150
Millan MJ (2003) The neurobiology and control of anxious states. Prog.Neurobiol. 70:83–244
Morgan CA, Wang S, Southwick SM, Rasmusson A, Hazlett G, Hauger RL, Charney DS (2000) Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol.Psychiatry 47:902–909
Morgan CA, Wang S, Rasmusson A, Hazlett G, Anderson G, Charney DS (2001) Relationship among plasma cortisol, catecholamines, neuropeptide Y, and human performance during exposure to uncontrollable stress. Psychosom.Med. 63:412–422
Nakajima M, Inui A, Asakawa A, Momose K, Ueno N, Teranishi A, Baba S, Kasuga M (1998) Neuropeptide Y produces anxiety via Y2-type receptors. Peptides 19:359–363
Naveilhan P, Neveu I, Arenas E, Ernfors P (1998) Complementary and overlapping expression of Yl, Y2 and Y5 receptors in the developing and adult mouse nervous system. Neuroscience 87:289–302
Naveilhan P, Canals JM, Valjakka A, Vartiainen J, Arenas E, Ernfors P (2001) Neuropeptide Y alters sedation through a hypothalamic Y1-mediated mechanism. Eur.J.Neurosci. 13:2241–2246
Nemeroff CB (2003) Anxiolytics: past, present, and future agents. J.Clin.Psychiatry 64 Suppl 3:3–6
Oberto A, Panzica G, Altruda F, Eva C (2000) Chronic modulation of the GABA(A) receptor complex regulates Yl receptor gene expression in the medial amygdala of transgenic mice. Neuropharmacology 39:227–234
Oberto A, Panzica GC, Altruda F, Eva C (2001) GABAergic and NPY-Y(l) network in the medial amygdala: a neuroanatomical basis for their functional interaction. Neuropharmacology 41:639–642
Painsipp E, Herzog H, Holzer P (2008a) Implication of neuropeptide-Y Y2 receptors in the effects of immune stress on emotional, locomotor and social behavior of mice. Neuropharmacology 55:117–126
Painsipp E, Wultsch T, Edelsbrunner ME, Tasan RO, Singewald N, Herzog H, Holzer P (2008b) Reduced anxiety-like and depression-related behavior in neuropeptide Y Y4 receptor knockout mice. Genes Brain Behav. 7:532–542
Palmiter RD, Erickson JC, Hollopeter G, Baraban SC, Schwartz MW (1998) Life without neuropeptide Y. Recent Prog.Horm.Res. 53:163–99:163–199
Park HJ, Chae Y, Jang J, Shim I, Lee H, Lim S (2005) The effect of acupuncture on anxiety and neuropeptide Y expression in the basolateral amygdala of maternally separated rats. Neurosci Lett. 377:179–184
Parker G, Hadzi-Pavlovic D, Greenwald S, Weissman M (1995) Low parental care as a risk factor to lifetime depression in a community sample. J.Affect.Disord. 33:173–180
Parker G, Wilhelm K, Mitchell P, Austin MP, Roussos J, Gladstone G (1999) The influence of anxiety as a risk to early onset major depression. J.Affect.Disord. 52:11–17
Parker G, Gladstone G, Mitchell P, Wilhelm K, Roy K (2000) Do early adverse experiences establish a cognitive vulnerability to depression on exposure to mirroring life events in adulthood? J.Affect.Disord. 57:209–215
Pich EM, Agnati LF, Zini I, Marrama P, Carani C (1993) Neuropeptide Y produces anxiolytic effects in spontaneously hypertensive rats. Peptides 14:909–912
Rasmusson AM, Hauger RL, Morgan CA, Bremner JD, Charney DS, Southwick SM (2000) Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol.Psychiatry 47:526–539
Redrobe JP, Dumont Y, Fournier A, Quirion R (2002a) The Neuropeptide Y (NPY) Yl Receptor Subtype Mediates NPY-induced Antidepressant-like Activity in the Mouse Forced Swimming Test. Neuropsychopharmacology 26:615–624
Redrobe JP, Dumont Y, Quirion R (2002b) Neuropeptide Y (NPY) and depression: From animal studies to the human condition. Life Sci. 71:2921–2937
Redrobe JP, Dumont Y, Herzog H, Quirion R (2003a) Characterization of neuropeptide Y, Y2 receptor knockout mice in two animal models of learning and memory processing. J.Mol.Neurosci. 22:159–166
Redrobe JP, Dumont Y, Herzog H, Quirion R (2003b) Neuropeptide Y (NPY) Y(2) receptors mediate behaviour in two animal models of anxiety: evidence from Y(2) receptor knockout mice. Behav.Brain Res. 141:251–255
Sainsbury A, Schwarzer C, Couzens M, Fetissov S, Furtinger S, Jenkins A, Cox HM, Sperk G, Hokfelt T, Herzog H (2002a) Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc.Natl.Acad.Sci.U.S.A 99:8938–8943
Sainsbury A, Schwarzer C, Couzens M, Herzog H (2002b) Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob mice. Diabetes 51:3420–3427
Sainsbury A, Schwarzer C, Couzens M, Jenkins A, Oakes SR, Ormandy CJ, Herzog H (2002c) Y4 receptor knockout rescues fertility in ob/ob mice. Genes Dev. 16:1077–1088
Sajdyk TJ, Vandergriff MG, Gehlert DR (1999) Amygdalar neuropeptide Y Yl receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur.J.Pharmacol. 368:143–147
Sajdyk TJ, Schober DA, Smiley DL, Gehlert DR (2002) Neuropeptide Y-Y(2) receptors mediate anxiety in the amygdala. Pharmacol.Biochem.Behav. 71:419–423
Sajdyk TJ, Shekhar A, Gehlert DR (2004) Interactions between NPY and CRF in the amygdala to regulate emotionality. Neuropeptides 38:225–234
Smialowska M, Wieronska JM, Domin H, Zieba B (2007) The effect of intrahippocampal injection of group II and III metobotropic glutamate receptor agonists on anxiety; the role of neuropeptide Y. Neuropsychopharmacology 32:1242–1250
Sorensen G, Lindberg C, Wortwein G, Bolwig TG, Woldbye DP (2004) Differential roles for neuropeptide Y Yl and Y5 receptors in anxiety and sedation. J.Neurosci.Res. 77:723–729
Southwick SM, Vythilingam M, Charney DS (2005) The psychobiology of depression and resilience to stress: implications for prevention and treatment. Annu.Rev.Clin.Psychol. 1:255–291
St Pierre JA, Dumont Y, Nouel D, Herzog H, Hamel E, Quirion R (1998) Preferential expression of the neuropeptide Y Yl over the Y2 receptor subtype in cultured hippocampal neurons and cloning of the rat Y2 receptor. BrJ.Pharmacol. 123:183–194
Stanley BG, Leibowitz SF (1984) Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sci. 35:2635–2642
Sweerts BW, Jarrott B, Lawrence AJ (2001) The effect of acute and chronic restraint on the central expression of prepro-neuropeptide Y mRNA in normotensive and hypertensive rats. J.Neuroendocrinol. 13:608–617
Tatemoto K (1982) Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc.Natl.Acad.Sci.U.S.A 79:5485–5489
Thiele TE, Marsh DJ, Marie L, Bernstein IL, Palmiter RD (1998) Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature 396:366–369
Thiele TE, Koh MT, Pedrazzini T (2002) Voluntary alcohol consumption is controlled via the neuropeptide Y Yl receptor. J.Neurosci. 22:RC208
Thorsell A, Carlsson K, Ekman R, Heilig M (1999) Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. Neuroreport 10:3003–3007
Thorsell A, Svensson P, Wiklund L, Sommer W, Ekman R, Heilig M (1998) Suppressed neuropeptide Y (NPY) mRNA in rat amygdala following restraint stress. Regul.Pept. 75-76:247–254
Thorsell A, Michalkiewicz M, Dumont Y, Quirion R, Caberlotto L, Rimondini R, Mathe AA, Heilig M (2000) Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc.Natl.Acad.Sci.U.S.A 97:12852–12857
Tong Y, Dumont Y, Shen SH, Quirion R (1997) Comparative developmental profile of the neuropeptide Y Yl receptor gene and protein in the rat brain. Mol.Brain Res. 48:323–332
Trinh T, Dumont Y, Quirion R (1996) High levels of specific neuropeptide Y/pancreatic polypeptide receptors in the rat hypothalamus and brainstem. Eur.J.Pharmacol. 318:R1–R3
Tsagarakis S, Rees LH, Besser GM, Grossman A (1989) Neuropeptide-Y stimulates CRF-41 release from rat hypothalami in vitro. Brain Res. 502:167–170
Tschenett A, Singewald N, Carli M, Balducci C, Salchner P, Vezzani A, Herzog H, Sperk G (2003) Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur.J.Neurosci. 18:143–148
Ueno N, Asakawa A, Satoh Y, Inui A (2007) Increased circulating cholecystokinin contributes to anorexia and anxiety behavior in mice overexpressing pancreatic polypeptide. Regul.Pept. 141:8–11
Vezzani A, Sperk G, Colmers WF (1999) Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 22:25–30
Wahlestedt C, Hakanson R (1986) Effects of neuropeptide Y (NPY) at the sympathetic neuroeffector junction. Can pre-and postjunctional receptors be distinguished? Med.Biol. 64:85–88
Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M (1993) Modulation of anxiety and neuropeptide Y-Yl receptors by antisense oligodeoxynucleotides. Science 259:528–531
Wang JZ, Lundeberg T, Yu L (2000) Antinociceptive effects induced by intraperiaqueductal grey administration of neuropeptide Y in rats. Brain Res. 859:361–363
Wieronska JM, Smialowska M, Branski P, Gasparini F, Klodzinska A, Szewczyk B, Palucha A, Chojnacka-Wojcik E, Pile A (2004) In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signaling. Neuropsychopharmacology 29:514–521
Wieronska JM, Szewczyk B, Palucha A, Branski P, Zieba B, Smialowska M (2005) Anxiolytic action of group II and III metabotropic glutamate receptors agonists involves neuropeptide Y in the amygdala. Pharmacol.Rep. 57:734–743
Woodhams PL, Allen YS, McGovern J, Allen JM, Bloom SR, Balazs R, Polak JM (1985) Immunohistochemical analysis of the early ontogeny of the neuropeptide Y system in rat brain. Neuroscience 15:173–202
Yilmazer-Hanke DM, Hantsch M, Hanke J, Schulz C, Faber-Zuschratter H, Schwegler H (2004) Neonatal thyroxine treatment: changes in the number of corticotropin-releasing-factor (CRF) and neuropeptide Y (NPY) containing neurons and density of tyrosine hydroxylase positive fibers (TH) in the amygdala correlate with anxiety-related behavior of wistar rats. Neuroscience 124:283–297
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer
About this paper
Cite this paper
Dumont, Y., Morales-Medina, J.C., Quirion, R. (2009). Neuropeptide Y and its Role in Anxiety-related Disorders. In: Shioda, S., Homma, I., Kato, N. (eds) Transmitters and Modulators in Health and Disease. Springer, Tokyo. https://doi.org/10.1007/978-4-431-99039-0_5
Download citation
DOI: https://doi.org/10.1007/978-4-431-99039-0_5
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-99038-3
Online ISBN: 978-4-431-99039-0
eBook Packages: MedicineMedicine (R0)